Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis DeutschlandfiledCriticalSanofi Aventis Deutschland
Priority to MYPI2013000528ApriorityCriticalpatent/MY157671A/en
Publication of MY157671ApublicationCriticalpatent/MY157671A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
THE PRESENT INVENTION REFERS TO THE USE OF LIXISENATIDE OR/AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2, FOR INDUCING WEIGHT LOSS IN DIABETES TYPE 2 PATIENTS OR/AND FOR PREVENTING WEIGHT GAIN IN DIABETES TYPE 2 PATIENTS.
MYPI2013000528A2010-08-302010-08-30Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
MY157671A
(en)
Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
Use of an amount of laquninimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a human subject suffering from a bdnf-related disease
Use of dronedarone or one of its pharmaceutically acceptable salts for preparing a medicament for the treatment of patients with arrhythmia and an increased creatinine level due to dronedarone administration
Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiasis and related diseases
Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation
Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level